Skip to content

A Clinical study ayurvedic medicines Chitrakadi Vati and Avipathi Churnam in the management of Hypothyroidism

An open label single arm clinical study on the combined effectiveness of Chitrakadi Vati and Avipathi Churnam in the management of Hypothyroidism

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/10/010066
Enrollment
30
Registered
2017-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Hypothyroidism

Interventions

Intervention1: Chitrakadi Vati Avipathi Churnam : Chitrakadi Vati Chitrakadi Vati will be given 1 tablet (250 mg) twice daily with lukewarm water before food for 84 days Avipathi Churnam Avipathi Chu

Sponsors

Dr Anoop A S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis will be made on the basis of TSH value more than 15-20 mU/l which may or may not be associated with decrease in T3 and T4 concentration and also with the signs and symptoms of Hypothyroidism one or multiplicity of these viz 1.tiredness, 2.dryness of skin, 3.feeling cold 4.hair loss, 5.constipation, 6.Weight gain with poor appetite 7.Hoarseness of voice, 8.muscle ache or stiffness, 9.menstrual disturbances, 10.Bradycardia 11.periorbital puffiness. Inclusion criteria include 1.Patients of age between 18 to 60 years of either gender 2.Patients already diagnosed as hypothyroidism with or without medication, 3.Patients with Primary hypothyroidism, 4.Patients with subclinical hypothyroidism, 5.Patients who are ready to sign the informed consent form

Exclusion criteria

Exclusion criteria: Exclusion criteria are as follows 1.Patients who have undergone any type of thyroid surgery, 2.Patients suffering from systemic diseases like Ischemic Heart Disease, Diabetes mellitus, carcinomas, 3.Patients suffering from congenital hypothyroidism, 4.Pregnancy and lactation, 5.Rapid progressive case of myxedema, 6.Hypothyroidism due to drug therapy (e.g. Amiodarone, Lithium, Interferon) 7.Hypothyroidism due to infiltrative diseases like Sarcoidosis,Scleroderma and Haemochromatosis

Design outcomes

Primary

MeasureTime frame
Assessment of subjective parameters will be done on 1st day,10th day, 41st day, 71st day and 90th day with the help of a suitable clinical scoring of hypothyroidism â?? BILLEWICZ SCORE The parameters in BILLEWICZ SCORE are the following signs and symptoms: Symptoms are Diminished sweating,Dry skin,Cold intolerance,Weight increase, Constipation, Hoarseness of voice and Deafness Signs are Slow movements, Coarse skin, Cold skin, Periorbital puffiness, Pulse rate and Ankle jerk Timepoint: 90 DAYS

Secondary

MeasureTime frame
Serum T3, T4, TSHTimepoint: 90 days

Countries

India

Contacts

Public ContactDr Diwakar Papurao Joshi

Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital

joshidpayu@gmail.com08172256460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026